Advertisement

Sleep and Breathing

, Volume 14, Issue 3, pp 201–207 | Cite as

Austrian Moderate Altitude Studies (AMAS): benefits of exposure to moderate altitudes (1,500–2,500 m)

  • Wolfgang SchobersbergerEmail author
  • Veronika Leichtfried
  • Michael Mueck-Weymann
  • Egon Humpeler
Original Article

Abstract

Objectives

A considerable part of the millions of Alpine tourists suffer from pre-existing diseases (e.g., metabolic syndrome) and high daily stress levels. The main goal of the Austrian Moderate Altitude Study (AMAS) was to investigate (a) the consequences of an active vacation at moderate altitude on the key parameters of the metabolic syndrome (AMAS I) and (b) the effects of a short active vacation on adult progenitor cells, bio-psychological parameters, and heart rate variability (HRV).

Methods

During the AMAS I pilot study (n = 22; 1,700 m a.s.l.) and AMAS I main study (n = 71; 1,700 m a.s.l. and 200 m a.s.l.), the volunteers simulated 3-week coached hiking vacations. For AMAS II, healthy volunteers (n = 13) participated in a 1-week active holiday at 1,700 m.

Results

There were significant improvements of obesity, hypertension, dyslipidemia, and insulin resistance of AMAS I patients after the vacation. In AMAS II participants, we found an increase in circulating endothelial progenitor cells as well as improvements in bio-psychological and HRV parameters.

Conclusions

Active vacations at moderate altitude are associated with a variety of positive health effects in persons with metabolic syndrome and in healthy subjects.

Keywords

Moderate altitude Health tourism Metabolic syndrome Exercise Hiking AMAS 

References

  1. 1.
    Inama K, Humpeler E (1981) Alpine Höhenlagen als Therapiefaktor bei Herz- Kreislauferkrankungen. In: Deetjen P, Humpeler E (eds) Medizinische Aspekte der Höhe. Georg Thieme Verlag, Stuttgart, pp 91–102Google Scholar
  2. 2.
    Mairbäurl H, Schobersberger W, Hasibeder W et al (1989) Exercise performance of hemodialysis patients during short-term and prolonged exposure to altitude. Clin Nephrol 32:31–39PubMedGoogle Scholar
  3. 3.
    Reaven GM (1996) Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473–486Google Scholar
  4. 4.
    Schobersberger W, Schmid P, Lechleitner M et al (2003) Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome. Eur J Appl Physiol 88:506–514CrossRefPubMedGoogle Scholar
  5. 5.
    Gunga HC, Fries D, Humpeler E et al (2003) Austrian Moderate Altitude Study (AMAS 2000)—fluid shifts, erythropoiesis, and angiogenesis in patients with metabolic syndrome at moderate altitude (1700 m). Eur J Appl Physiol 88:497–505CrossRefPubMedGoogle Scholar
  6. 6.
    National Cholesterol Education Program (2001) Executive summary of the Third Report of The (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRefGoogle Scholar
  7. 7.
    World Health Organisation (1999) Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. World Health Organisation, GenevaGoogle Scholar
  8. 8.
    Greie S, Humpeler E, Gunga HC et al (2006) Improvement of metabolic syndrome markers through altitude specific hiking vacation. J Endocrinol Invest 29:497–504PubMedGoogle Scholar
  9. 9.
    Mair J, Hammerer-Lercher A, Mittermayr M et al (2008) 3-week hiking holidays at moderate altitude do not impair cardiac function in individuals with metabolic syndrome. Int J Cardiol 123:186–188CrossRefPubMedGoogle Scholar
  10. 10.
    Frick M, Rinner A, Mair J et al (2006) Transient impairment of flow-mediated vasodilation in patients with metabolic syndrome at moderate altitude (1700 m). Int J Cardiol 109:82–87CrossRefPubMedGoogle Scholar
  11. 11.
    Schobersberger W, Greie S, Humpeler E et al (2005) Austrian Moderate Altitude Study (AMAS 2000): erythropoietic activity and Hb-O2 affinity during a 3-week hiking holiday at moderate altitude in persons with metabolic syndrome. High Alt Med Biol 6:167–177CrossRefPubMedGoogle Scholar
  12. 12.
    Strauss-Blasche G, Riedmann B, Schobersberger W et al (2004) Vacation at moderate and low altitude improves perceived health in individuals with metabolic syndrome. J Travel Med 11:300–304PubMedGoogle Scholar
  13. 13.
    St-Onge M, Mignault D, Allison DB et al (2007) Evaluation of a portable device to measure daily energy expenditures in free-living adults. Am J Clin Nutr 85:742–749PubMedGoogle Scholar
  14. 14.
    Umemura T, Higashi Y (2008) Endothelial progenitor cells: therapeutic target for cardiovascular diseases. J Pharmacol Sci 108:1–6CrossRefPubMedGoogle Scholar
  15. 15.
    Brunner S, Engelmann MG, Franz WM (2008) Stem cell mobilisation for myocardial repair. Expert Opin Biol Ther 8:1675–1690CrossRefPubMedGoogle Scholar
  16. 16.
    Adams V, Lenk K, Linke A et al (2004) Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Thromb Vasc Biol 24:684–690CrossRefGoogle Scholar
  17. 17.
    Steiner S, Niessner A, Ziegler S et al (2005) Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 181:305–310CrossRefPubMedGoogle Scholar
  18. 18.
    Theiss HD, Adam M, Greie S et al (2008) Increased levels of circulating progenitor cells after 1-week sojourn at moderate altitude (Austrian Moderate Altitude Study II, AMAS II). Resp Physiol Neurobiol 160:232–238CrossRefGoogle Scholar
  19. 19.
    Bech P (2004) Measuring the dimensions of psychological general well-being by the WHO-5. QoL Newsletter 32:15–16Google Scholar
  20. 20.
    Kallus KW (2005) Erholungs-Belastungs-Fragebogen. Swets & Zeitlinger, LisseGoogle Scholar
  21. 21.
    Eckberg DL (1997) Sympathovagal balance: a critical appraisal. Circulation 96:3224–3232PubMedGoogle Scholar
  22. 22.
    Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Eur Heart J 17:354–381Google Scholar
  23. 23.
    Lombardi F (2002) Clinical implications of present physiological understanding of HRV components. Card Electrophysiol Rev 6:245–249CrossRefPubMedGoogle Scholar
  24. 24.
    Mück-Weymannn M, Moesler T, Joraschky P et al (2002) Depression modulates autonomic cardiac control: a physiopsychological pathway linking depression and mortality? Germ J Psych 5:67–69Google Scholar
  25. 25.
    Porges SW (1995) Cardiac vagal tone: a physiological index of stress. Neurosci Biobehav Rev 19:225–233CrossRefPubMedGoogle Scholar
  26. 26.
    Alberti KGMM, Zimmet P, Shwa J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome – a new worldwide definition. Lancet 366:1059–1062CrossRefPubMedGoogle Scholar
  27. 27.
    Räikkönen K, Keltikangas-Järvinen L, Hautanen A et al (1997) Neuroendocrine mechanisms in chronic perceived stress: associations with the metabolic syndrome. Endocrinol Metab 4:247–254Google Scholar
  28. 28.
    Gump BB, Matthews KA (2000) Are vacations good for your health? The 9-year mortality experience after the multiple risk factor intervention trial. Psychosom Med 62:608–61PubMedGoogle Scholar
  29. 29.
    Kop WJ, Vingerhoets AD, Kruithof GJ et al (2003) Risk factors for myocardial infarction during vacation travel. Psychosom Med 65:396–401CrossRefPubMedGoogle Scholar
  30. 30.
    Caroll S, Dudfield M (2004) What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. Sports Med 34:371–418CrossRefGoogle Scholar
  31. 31.
    Henkel V, Mergl R, Kohnen R et al (2003) Identifying depression in primary care: a comparison of different methods. Br Med J 226:200–201CrossRefGoogle Scholar
  32. 32.
    Hottenrott K, Hoos O, Esperer HD (2006) Heart rate variability and physical exercise. Current status. Herz 31:544–552CrossRefPubMedGoogle Scholar
  33. 33.
    Nolan RP, Jong P, Barry-Bianchi SM et al (2008) Effects of drug, biobehavioral and exercise therapies on heart rate variability in coronary artery disease: a systematic review. Eur J Cardiovasc Prev Rehabil 15:386–396CrossRefPubMedGoogle Scholar
  34. 34.
    Perini R, Milesi S, Biancardi L, Veicsteinas A (1996) Effects of high altitude acclimatization on heart rate variability in resting humans. Eur J Appl Physiol Occup Physiol 73:521–528CrossRefPubMedGoogle Scholar
  35. 35.
    Eckberg DL (2003) The human respiratory gate. J Physiol 548:339–352PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Wolfgang Schobersberger
    • 1
    Email author
  • Veronika Leichtfried
    • 1
  • Michael Mueck-Weymann
    • 2
  • Egon Humpeler
    • 1
    • 3
  1. 1.Institut für Sport-, Alpinmedizin und Gesundheitstourismus (ISAG), TILAK Innsbruck und UMITHall/TirolAustria
  2. 2.Institut für Verhaltensmedizin und Prävention, UMITHallAustria
  3. 3.Institut Humpeler & Schobersberger, Forschungsinstitut für Urlaubs-, und Freizeitmedizin sowie GesundheitstourismusBregenzAustria

Personalised recommendations